These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34919695)

  • 1. Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples.
    Welby E; Rehborg RJ; Harmelink M; Ebert AD
    Hum Mol Genet; 2022 Jun; 31(11):1830-1843. PubMed ID: 34919695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy.
    Sison SL; Patitucci TN; Seminary ER; Villalon E; Lorson CL; Ebert AD
    Hum Mol Genet; 2017 Sep; 26(17):3409-3420. PubMed ID: 28637335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.
    Magen I; Aharoni S; Yacovzada NS; Tokatly Latzer I; Alves CRR; Sagi L; Fattal-Valevski A; Swoboda KJ; Katz J; Bruckheimer E; Nevo Y; Hornstein E
    Eur J Neurol; 2022 Aug; 29(8):2420-2430. PubMed ID: 35510740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of LARGE1 abundance in patients and a mouse model of 5q-associated spinal muscular atrophy.
    Roos A; Schmitt LI; Hansmann C; Hezel S; Salmanian S; Hentschel A; Meyer N; Marina AD; Kölbel H; Kleinschnitz C; Schara-Schmidt U; Leo M; Hagenacker T
    Acta Neuropathol; 2024 Mar; 147(1):53. PubMed ID: 38470509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment.
    Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN
    Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of plasma microRNAs to nusinersen treatment in patients with SMA.
    Zaharieva IT; Scoto M; Aragon-Gawinska K; Ridout D; Doreste B; Servais L; Muntoni F; Zhou H
    Ann Clin Transl Neurol; 2022 Jul; 9(7):1011-1026. PubMed ID: 35584175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen.
    Šimić G; Vukić V; Babić M; Banović M; Berečić I; Španić E; Zubčić K; Golubić AT; Barišić Kutija M; Merkler Šorgić A; Vogrinc Ž; Lehman I; Hof PR; Sertić J; Barišić N
    CNS Neurosci Ther; 2024 Mar; 30(3):e14051. PubMed ID: 36513962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy.
    Dobelmann V; Roos A; Hentschel A; Della Marina A; Leo M; Schmitt LI; Maggi L; Schara-Schmidt U; Hagenacker T; Ruck T; Kölbel H
    J Neurol; 2024 Oct; 271(10):7000-7011. PubMed ID: 39240344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen.
    Trifunov S; Natera-de Benito D; Carrera-García L; Codina A; Expósito-Escudero J; Ortez C; Medina J; Torres Alcala S; Bernal S; Alias L; Badosa C; Balsells S; Alcolea D; Nascimento A; Jimenez-Mallebrera C
    J Neuromuscul Dis; 2023; 10(4):653-665. PubMed ID: 37038823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
    Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
    Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen.
    Totzeck A; Stolte B; Kizina K; Bolz S; Schlag M; Thimm A; Kleinschnitz C; Hagenacker T
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen.
    Andrés-Benito P; Vázquez-Costa JF; Ñungo Garzón NC; Colomina MJ; Marco C; González L; Terrafeta C; Domínguez R; Ferrer I; Povedano M
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.
    Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H
    Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen.
    Garofalo M; Bonanno S; Marcuzzo S; Pandini C; Scarian E; Dragoni F; Di Gerlando R; Bordoni M; Parravicini S; Gellera C; Masson R; Dosi C; Zanin R; Pansarasa O; Cereda C; Berardinelli A; Gagliardi S
    Biol Direct; 2023 Sep; 18(1):57. PubMed ID: 37705059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy.
    Orbach R; Sagi L; Sadot E; Tokatly Latzer I; Shtamler A; Zisberg T; Fattal-Valevski A
    Muscle Nerve; 2022 Dec; 66(6):762-766. PubMed ID: 36214191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.